Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to ...

Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of ...

Analysts are estimating that Biogen will report an earnings per share (EPS) of $3.89. The announcement from Biogen is eagerly ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed ...

Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also got the FDA no-go ...

Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.

C5aR1 plays an important role in the immune cascade that causes tissue inflammation, particularly in neutrophil-mediated conditions. There’s an obvious overlap with Biogen’s own izastobart, an ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...